

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07K 14/435, C08B 37/00, A61K 39/17, 31/725, G01N 33/50	A1	(11) International Publication Number: WO 95/25745 (43) International Publication Date: 28 September 1995 (28.09.95)
(21) International Application Number: PCT/IB95/00208	(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 24 March 1995 (24.03.95)	Published <i>With international search report.</i>	
(30) Priority Data: 9405846.8 24 March 1994 (24.03.94) GB		
(71)(72) Applicant and Inventor: MISEVIC, Gradimir [CH/CH]; Hermann Albrecht Strasse 15, CH-4058 Basel (CH).		
(74) Agent: FLEURANCE, Raphaël; Office Beau de Loménie, 51, avenue Jean-Jaurès, Boîte postale 7073, F-69301 Lyon Cédex 07 (FR).		
(54) Title: GLUCOSE CONTAINING PROTEOGLYCAN OR ACID GLYCAN AND THEIR PHARMACEUTICAL USE		
(57) Abstract <p>A class of proteoglycans containing fucosylated acidic glycans, e.g., as produced by marine sponges and sea urchin embryos, have been found to stimulate selective proliferation of mammalian natural killer (NK) cells and $\gamma\delta$T cells. These compounds are useful as pharmaceuticals, particularly as immunostimulants, e.g., in the treatment of cancer and viral infections.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BH	Bahamas	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BR	Bolivia	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Slovenia
CH	Switzerland	KZ	Kazakhstan	SK	Slovakia
CI	Côte d'Ivoire	LI	Lichtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	TD	Chad
CR	Costa Rica	LU	Luxembourg	TG	Togo
CS	Czechoslovakia	LV	Latvia	TJ	Tajikistan
CZ	Czech Republic	MC	Monaco	TT	Trinidad and Tobago
DE	Germany	MD	Republic of Moldova	UA	Ukraine
DK	Denmark	MG	Madagascar	US	United States of America
ES	Spain	ML	Mali	UZ	Uzbekistan
FI	Finland	MN	Mongolia	VN	Viet Nam
FR	France				
GA	Gabon				

FUCOSE CONTAINING PROTEOGLYCAN OR ACID GLYCAN AND THEIR PHARMACEUTICAL USE

TECHNICAL FIELD :

5

This invention relates to a class of proteoglycans having fucosylated acidic glycan side chains bound to a protein backbone which have been found to stimulate selectively proliferation of natural killer (NK) cells and/or $\gamma\delta$ T cells. They are useful as immunostimulants, e.g., in the treatment of cancer and viral infections.

10

PRIOR ART :

15

The proteoglycans of the invention are produced by proliferating cells, for example by sponge cells, sea urchin cells, and, in the case of higher animals (including humans), by embryonic cells and tumor cells. In the natural proteoglycan form, the compounds are large (ca. 5000 to 30,000 kD) extracellular or membrane-bound molecules having a protein backbone which is glycosylated with acidic glycan chains having an unusual polysaccharide sequence containing internal fucose. The structure of the acidic glycan side chains of the proteoglycan isolated from the marine sponge *Microciona prolifera* has been partially characterized (Spillmann, et al., J. Biol. Chem. (1993) 268: 13378-13387, contents incorporated herein by reference), and we have previously shown that this proteoglycan is involved in cellular aggregation (Misevic, et al., J. Biol. Chem. (1987) 262: 5870-5877; Misevic, et al., J. Biol. Chem. (1990) 265: 20577-20584 ; Misevic, et al., J. Biol. Chem. (1993) 268: 4922-4929, contents of all of these articles incorporated herein by reference). The previously undescribed protein backbone of the *Microciona prolifera* proteoglycan has now been isolated and characterized, and novel proteoglycans derived from sponges of other genera have also been characterized, as described below.

20

BRIEF DESCRIPTION OF THE INVENTION :

25

It has now surprisingly been discovered that these compounds are potent stimulators of NK cells and $\gamma\delta$ T cells. In particular, compounds of the invention isolated from an organism of all the phyla and preferably :

30

♦ from organisms of the Phylum Porifera e.g., of the class Demospongiae, especially of the order Poecilosclerida, family Microcionidae (e.g., of the genus *Microciona*), or family Mycalidae (e.g., of the genus *Mycala*), or the order Halichondrida, family Halichondridae (e.g., of the genus *Halichondria*), or the order Hadromerida, family

Clionidae (e.g., of the genus *Cliona*), or the order Haplosclerida, family Haliclonidae (e.g., of the genus *Haliclona*),

♦ and/or from organisms of the phylum Echinodermata.

These compounds have been shown to stimulate selectively different clones of NK cells and $\gamma\delta$ T cells. Moreover, it has been found that compounds of the invention have significant anticancer, especially antimetastatic, effects *in vivo*. It is believed that these anticancer effects are due to stimulation *in vivo* of NK cells and/or $\gamma\delta$ T cells. The precise mechanism of this stimulation is unclear, but without intending to be bound by a particular theory, we suggest that these cells may be stimulated by polyvalent interactions with fucosylated acidic glycans of the class described herein and in this way can identify and destroy hyperproliferating cells expressing similar glycan structures. In a pathogenic case, where the hyperproliferating cells are not destroyed in this manner, it is believed that although the hyperproliferating cells produce these acidic glycans, they shed them or present them in monovalent form or other nonstimulatory or inhibitory form, thereby evading detection and destruction by NK cells and/or $\gamma\delta$ T cells specific for such acidic glycans. Application of the compounds of the invention stimulates NK cells and/or $\gamma\delta$ T cells specific for such cancer cells, thereby leading to their destruction. Additionally, the compounds of the invention are useful for stimulating NK cells and/or $\gamma\delta$ T cells against viral or retroviral infections. Finally, in monovalent form, the compounds of the invention are useful for inhibiting the activation of NK cells and/or $\gamma\delta$ T cells, thereby finding utility as immunosuppressants.

The compounds of the invention are selective in their action, in that particular compounds of the invention stimulate only particular clones or subpopulations of NK cells or $\gamma\delta$ T cells. No significant stimulation of B cells or $\alpha\beta$ T cells is observed, so undesirable immunostimulation, e.g., an allergic or autoimmune response, is avoided. Despite this selectivity, all humans tested, from a variety of ethnic and racial groups, have cell populations capable of being significantly stimulated by the compounds of the invention. Compounds having the glycan structures of the class described herein are found in a wide variety of hyperproliferating cells from sponges to human tumors, thus the basic structure of the compounds is highly conserved. It is hypothesized that compounds of the class described herein act as signals for stimulating the body's defenses against unwanted proliferation of cancerous or infected cells, and that cancers or resistant viral infections may arise when, as described above, these compounds are secreted in nonstimulatory form. Among the examples described herein, it is noted that compounds of the invention isolated from those of the genus *Microciona* are more effective in stimulating NK cells, as described in example 1 below, whereas compounds isolated from the genus *Halichondria* are more

effective in stimulating $\gamma\delta$ T cells, as described in example 9, thus selectivity among cell types receptive to this stimulation is also possible.

DETAILED DESCRIPTION OF THE INVENTION

5

The invention thus provides

1. Fucose-containing proteoglycans and acidic glycans, and/or fragment(s) thereof, preferably proteoglycans, e.g., isolated or capable of being isolated from embryonic 10 or neoplastic tissue or from an organism of all the phyla and preferably from an organism of the phylum Porifera, e.g., as described above, especially of the genera *Micrciona* and/or *Halichondria* and/or *Mycale* and/or *Cliona* and/or from an organism of the phylum Echinodermata especially of the genus *Lytechinus* for use as a pharmaceutical or therapeutic agent *in vivo* or for *ex vivo* therapy ; and pharmaceutical compositions comprising such compounds in combination with a pharmaceutically acceptable carrier or diluent.

15

2. Novel fucose-containing proteoglycans and acidic glycans, and or fragments thereof, preferably proteoglycans, isolated or capable of being isolated from organisms of the genus *Halichondria* and/or *Mycale* and/or *Cliona*.

20

3. Novel fucose-containing acidic glycans capable of being isolated from a sea urchin of the genus *Lytechinus*,

25

4. A Fucose-containing acidic glycan for use as a pharmaceutical or therapeutic agent *in vivo* or for *ex vivo* therapy ; and pharmaceutical compositions comprising such compounds in combination with a pharmaceutically acceptable carrier or diluent ; and capable of binding to monoclonal antibodies of the type of those named "Block 2" and described in the reference "Misevic, et al., J. Biol. Chem. (1993) 268 : 4922-4929,

30

5. A method of stimulating the proliferation of mammalian, e.g., human, NK cells and/or $\gamma\delta$ T cells comprising contacting said cells with a compound of the invention (a fucose-containing proteoglycan and acidic glycan, and/or fragment thereof, preferably a proteoglycan and/or fragment(s) thereof, e.g., isolated or capable of being isolated from embryonic or neoplastic tissue or from an organism of the phylum Porifera, or Echinodermata e.g., as described above, especially of the genera *Micrciona* and/or *Halichondria* and/or *Mycale* and/or *Cliona*, and/or of the phylum Echinodermata especially of the genus *Lytechinus*, in an *ex vivo* setting or *in vivo*, e.g., as a vaccine; or a method of treating cancer (e.g., preventing or inhibiting onset, growth, or metastasis of a tumor), or

35

treating or preventing a viral or retroviral infection, in a mammal, e.g., man; comprising administering a pharmaceutically effective amount of a compound of the invention to a patient in need of such treatment; or the use of a compound of the invention in the manufacture of a medicament for treatment or prevention of cancer or viral or retroviral infections.

5 6. The use of a fucose-containing proteoglycan or acidic glycan, or fragment thereof, preferably a proteoglycan and/or fragment(s) thereof, e.g., isolated or capable of being isolated from embryonic or neoplastic tissue or from an organism of the phylum 10 *Porifera* and/or *Echinodermata*, e.g., as described above, especially of the genera *Microciona* and/or *Halichondria*, and/or *Mycale* and/or *Ciona* for the phylum *Porifera*, especially of the genus *Lytechinus* for the phylum *Echinodermata* for *ex vivo* stimulation of proliferation of NK cells and/or $\gamma\delta$ T cells.

15 7. A method for screening for or detecting an immunosuppressive (e.g., NK cell and/or $\gamma\delta$ T cell inhibitory) compound comprising measuring proliferation of NK cells and/or $\gamma\delta$ T cells in a system containing an NK cell or $\gamma\delta$ T cell stimulatory concentration of a compound of the invention in the presence and absence of a test compound; and compounds identified using such a method.

20 8. A gene coding for a protein capable of post-translational glycosylation to form the proteoglycan of the invention, vectors containing such a gene, and transformed cells, especially (i) production cells, e.g., sponge cells, incorporating such a gene for use in producing the desired proteoglycan at enhanced levels or (ii) cancer cells removed from a patient, transformed with the gene so as to express the proteoglycan in stimulatory form, 25 irradiated, and reintroduced into the patient. The gene for *Microciona* proteoglycan can be isolated, for example, using oligonucleotide probes of a cDNA library based on the disclosed amino acid sequences.

30 35 Appropriate dosages of the compounds of the invention will of course vary, e.g. depending on the condition to be treated (for example the disease type or the nature of resistance), the effect desired, and the mode of administration. In general however satisfactory results are obtained on administration orally, rectally, nasally, topically, or parenterally, e.g. intravenously, for example by i.v. drip or infusion, at dosages on the order of from 0.01 to 2.5 up to 5 mg/kg, e.g. on the order of from 0.05 or 0.1 up to 1.0 mg/kg. Suitable dosages for patients are thus on the order of from 0.5 to 125 up to 250 mg i.v., e.g. on the order of from 2.5 to 50 mg i.v.. Pharmaceutical compositions of the invention may be

manufactured in conventional manner, in a suitable aqueous carrier, for example sterile buffered physiological saline.

For *ex vivo* stimulation of cells, as described more fully in the example below, a
5 suitable amount, e.g., at least 10 ml, of the patient's blood is removed, peripheral blood mononuclear cells are isolated from the blood, placed in a complete medium in the presence of a stimulatory concentration of a compound of the invention, e.g., 10-500 µg/ml, ca. 100 µg/ml, optionally in the presence of IL-2, and the culture is maintained until a significant increase in the population of the desired cell type is observed, e.g., ca. 2-4 weeks.
10 Following stimulation of the cells, the cells are isolated from the medium, placed in an injection solution, e.g., sterile buffered physiological saline or plasma, and injected back into the patient. The compound of the invention for this use can, for example, be a proteoglycan or acidic glycan derived from a marine sponge as described in the examples, but may also be a proteoglycan, acidic glycan or fragment thereof isolated from a culture of the cancerous cells to be treated.
15

INDUSTRIAL APPLICATION :

The compounds can be useful notably as pharmaceuticals, particularly as
20 immunostimulants, e.g. in the treatment of cancer and viral infections.

EXAMPLES :

EXAMPLE 1 : Preparation of proteoglycan and acidic glycans from *Microciona prolifera*

a. Extraction of proteoglycan from *Microciona prolifera*.

Fresh marine sponges (*Microciona prolifera*) collected from the Cape Cod area (USA) are rinsed with 0.5M NaCl, 0.18g/l NaHCO₃ (buffer A) and cut into cubes 1x1 cm. The cubes are incubated in the buffer A (50% suspension) for 12h at +4°C under gentle rotation. After filtration of the sponge cube suspension through cheese cloth, the cubes were two more times extracted with the buffer A using the same incubation conditions. The supernatants are either combined or separately centrifuged at 3000 x g for 30 min at +4°C, and the obtained supernatant is again centrifuged at 12,000 x g for 40 min at +4°C. CaCl₂ is added to the supernatant to a concentration of 20mM. After 2-12 h gentle shaking at room temperature, the precipitated proteoglycan is centrifuged at 3000 x g for 20 min at room temperature. The pelleted proteoglycan is dissolved in at least 20 volumes of 0.5 M NaCl, 2mM CaCl₂, 20mM Tris pH 7.4 (buffer B) and centrifuged at 10,000 x g for 30 min at +4°C to remove insoluble material. Supernatant was centrifuged at 100,000 x g for 4h at
25
30
35 +4°C to remove insoluble material.

+4°C, and the pelleted proteoglycan redissolved in buffer B at concentration of 1-2 mg/ml. To the dissolved proteoglycan in buffer B solid CsCl is added to make a 50% concentration, and the solution is centrifuged in a SW rotor at 100,000 x g for 36h at room temperature. The pelleted proteoglycan is dialyzed against buffer B and stored at +4°C in the presence of 5 0.05% NaN₃.

The purified proteoglycan thus obtained exhibits the following characteristics:

- 1) Molecular mass: 19,000 kD ± 20%.
- 10 2) Sedimentation coefficient S_{20w}: 58 ± 20%.
- 3) Stability to enzymes: Not digestible with Chondroitinase A, B, C, Heparinase, Hepitinase, Hyaluronidase and Keratinase.
- 4) Gelation: Forms gel in aqueous salt solution containing more than 6mM CaCl₂ or in deionized water.
- 15 5) Shape determined with atomic force microscopy in liquid and electron microscopy: circle of 400-500nm diameter with 10-20 arms 200-300nm long.
- 6) Stability: circle portion dissociates from arms in aqueous salt solutions containing less than 1mM CaCl₂ or in the presence of EDTA.
- 7) Ca²⁺ binding determined by flame ionization spectrometry: binds ca. 7000 moles of Ca²⁺/mole of proteoglycan at 2mM CaCl₂ and ca. 70,000 moles of Ca²⁺/mole of proteoglycan at 20mM CaCl₂.
- 20 8) Dissociation fingerprinting: Dissociation of proteoglycan by 1%SDS at 100°C gave nine fragments ranging from 38 - 1500 kD on a 5-20% linear gradient polyacrylamide gel after electrophoresis. These fragments had apparent molecular masses of ca. 1500 kD, 500 kD, 250 kD, 150 kD, 148 kD, 135 kD, 108 kD, 70 kD, and 38 kD.
- 25 9) EDTA and heating at 80°C produced fragments of Mr 1500 × 10³, 250 × 10³ on gel filtration chromatography. Trypsin digestion produced fragments of Mr 124 × 10³, 70 × 10³, 27 × 10³, 10 × 10³ on gel filtration chromatography.
- 30 10) Table I shows approximate amino acid (measured by HPLC pico-tag) and approximate total sugar composition (measured by gas chromatography after methanolysis, reacetylation and silylation): This proteoglycan consists of approximatively 36 % by weight proteins and 64 % by weight carbohydrates.

Table I

Intact proteoglycan (PG)			Isolated glycans		
	<u>mol amino acid</u> <u>mol PG</u>	(mol %)	<u>mol amino acid</u> <u>mol glycan</u>	(mol %)	
5	Asx	12,736	13.4	1.2	33.4
	Thr	8,196	8.6	0.6	16.7
	Ser	6,179	6.7	0.3	8.4
	Glx	11,475	12.0	0.7	19.5
	Pro	5,611	6.0	0.0	0.0
	Gly	12,484	13.1	0.5	13.8
	Ala	9,205	9.7	0.1	2.8
	Val	5,296	5.8	0.0	0.0
	Met	693	0.8	0.0	0.0
10	Ile	3,287	4.5	0.0	0.0
	Leu	6997	7.4	0.1	2.7
	Tyr	3,972	4.2	0.0	0.0
	Phe	3,530	3.7	0.1	2.7
	His	945	1.0	0.0	0.0
	Lys	1,261	1.3	0.0	0.0
	Arg	1,765	1.8	0.0	0.0
Total			94,629	100.0	3.6
25					
	<u>mol carbohydrate</u> <u>mol PG</u>	(mol %)	<u>mol carbohydrate</u> <u>mol glycan</u>	(mol %)	
30	Fucose	15,069	33.9	9.9	34.7
	GlcUA	4,602	10.3	2.0	7.2
	Man	4,602	9.1	2.7	9.6
	Gal	10,907	24.5	7.4	26.1
	GlcNAc	9,836	22.2	6.3	22.3
	Total	44,449	100.0	28.3	100.0
35					
	<u>mol /mol PG</u>				
	SO ₄ ²⁻		≥8,241		

Standard deviation is less than 20% of each value. Asx signifies Asn or Asp; Glx signifies Glu or Gln. It is also noted that apparent amounts of Ile and Leu are somewhat variable depending on the preparation. The amount of uronic acid determined colorimetrically is usually 2 times higher than the amount determined by gas chromatography. SO₄⁻ was determined by HPLC ion chromatography after hydrolysis of PG.

5

The N-terminal sequence of the backbone of the molecule is as follows:

Seq. I Pro-Leu-Phe-Thr-Val-Pro-Ile-Tyr-Val-Pro-Glu-Asp-Gln-Leu
10 Seq. II Pro-Glu-Val-Gly-Val-Pro-Ile-Tyr-Val-Pro-Glu-Asp-Gln-Leu
Seq. III Pro-Val-Val-Gly-Val-Pro-Ile-Tyr-Val-Pro-Glu-Asp-Gln-Leu
preferably Sequence I.

Trypsin digestion of the molecule provides peptides having the sequences:

15 Seq. IV Phe-Val-Val-Met-Arg
Seq. V Pro-Gln-Asp-Pro-Phe
Seq. VI Leu-Ala-Gly-Val-Val-Ile
Seq. VII Pro-Gln-Ala-Ser-Ser-Gly
20 Seq. VIII Ala-Ala-Gln-Trp-Ile-Gly-Gln-Lys

b. Isolation of acidic glycans from the *Microciona prolifera* proteoglycan

Frozen proteoglycan as obtained above is extracted with water/methanol/chloroform 25 3/8/4 V/V/V, and the nonlipid fraction was pelleted by centrifugation at 4000 x g for 15 min at +4°C. This extraction is repeated and the pellet is dried under a vacuum. The pellet is wetted in ethanol and resuspended in 0.1 M Tris pH 8, 1mM CaCl₂, and 100-200µg Pronase (Calbiochem) (preincubated for 30 min at 60°C in 0.1M Tris pH 8, 1mM CaCl₂ per 1-2mg dried powder material), and the pellet is digested at 60°C for three days. Two more 30 equivalent portions of preincubated pronase are added at 24 h intervals. DNase I is then added (30µg) and incubation is continued at 37°C in the presence of 10mM MgCl₂. The digested sample is then treated again with pronase and chromatographed through G-25 Sephadex (Pharmacia) column eluted with 10mM pyridine acetate pH 5, void volume fractions are collected and lyophilized, and the glycans thus obtained are dissolved in 50mM 35 NaOH in the presence of 1M NaHBO₄ and incubated at 45°C for 16h (NaOH treatment may also be omitted). The glycans are passed through Dowex AG 50W-X8 column in H⁺ form (Bio-Rad) eluted with water, nonbound glycans are immediately neutralized and electrophoresed on a 5-20% or 10-40% linear polyacrylamide gradient gels (Tris/borate-

EDTA), and separated acidic glycans of $\text{Mr } 200 \times 10^3$ are eluted from gels. (Optionally, the acidic glycans can be separated by gel filtration rather than electrophoresis). The isolated acidic glycan molecules are desalted using P-2 column (Bio-Rad) eluted with 10mM pyridine acetate pH 5, lyophilized and stored at -20°C.

5

The acidic glycan fraction is comprised of two major glycans of apparent molecular mass determined by gel electrophoresis using glycosaminoglycan standards of ca. 200 kD and 6 kD. The glycans have the following molar composition (expressed as moles of monosaccharide units / mole of glycan), as determined by gas chromatography, as shown in

10 Table II:

Table II


	<u>200 kD glycan</u>	<u>6 kD glycan</u>
15	Fuc	680
	Man	20
	Gal	180
	GlcNAc	190
20	GlcUA	320
	Asn	1

Standard deviation is less than 20% of each value. Per mole of proteoglycan, there are 20 moles of the 200 kD glycan and 1000 moles of the 6 kD glycan. The glycans are not digestible with Chondroitinase A, B, C, Heparinase, Heparitinase, Hyaluronidase or Keratinase. They are soluble in aqueous solutions and do not form gels in 6mM CaCl₂ salt solutions. At higher concentrations, e.g. > 1 mg/ml water, they will undergo hydrolysis at room temperature.

25


After partial acid hydrolysis of isolated glycans fragments were purified by ion exchange chromatography and high performance liquid chromatography. Methylation analysis, sequential enzymatic and chemical degradation, ¹H-NMR spectroscopy, and fast atom bombardment-mass spectrometry of three purified fragments showed following oligosaccharide structures :

Structure 1




5 is repeated 1000 times per mole proteoglycan.

Structure 2



10 is repeated 2000 times per mole proteoglycan.

Structure 3



15 is repeated 2000 times per mole proteoglycan.

EXAMPLE 2 : Preparation of proteoglycans and acidic glycans from *Halichondria panicea*

20 Extraction of proteoglycan from *Halichondria panicea* and isolation of acidic glycans from *Halichondria panicea* proteoglycan is performed as described in example 1 for *Microciona prolifera*. The proteoglycan thus obtained has the following characteristics:

- 25 1) Molecular mass: 10,000 kD \pm 20%.
- 2) Sedimentation coefficient of S_w 42 \pm 20%.
- 3)
- 4) Stability to enzymes: Not digestible with Chondroitinase A, B, C, Heparinase, Heparitinase, Hyaluronidase and Keratinase.
- 5) Gelation: Forms gel in aqueous salt solution containing more than 6mM CaCl₂ or in deionized water.

30 This proteoglycan consists of approximately 79 % protein and 21 % carbohydrate by weight. It has an approximate amino acid composition (as measured by HPLC pico-tag) and approximate total sugar composition (as measured by gas chromatography) as shown in Table III :

Table III

Amino acid composition and carbohydrate composition

5 Intact proteoglycan (PG)

	amino acid	mol %
10	Asx	9.1
	Glx	9.2
	Ser	7.0
	Gly	9.9
	Arg	7.6
	Thr	10.2
15	Ala	7.0
	Pro	8.2
	Tyr	4.6
	Val	8.6
	Met	2.5
	Cys	0.1
20	Ile	6.0
	Leu	5.5
	Phe	4.8
	Total	100.0
	carbohydrate	(mol %)
25	Fuc	12.5
	Xyl	1.9
	GlcUA	3.2
	GalUA	1.7
	Man	16.7
	Gal	36.2
30	Glc	13.6
	GlcNAc	14.2
	Total	100.0
mol/mol PG		
$\geq 6,250$		
SO_4^-		

Standard deviation is less than 20% of each value. Asx signifies Asn or Asp; Glx signifies Glu or Gln. It is also noted that apparent amounts of Ile and Leu are somewhat variable depending on the preparation. The amount of uronic acid determined colorimetrically is usually 2 times higher than the amount determined by gas chromatography. SO₄²⁻ was determined by HPLC ion chromatography after hydrolysis of PG.

5

Isolation of acidic glycans from this proteoglycan in the manner described in example 1 gives seven glycans having apparent molecular mass determined by gel electrophoresis using glycosaminoglycan standards of ca. > 1000 kD, 600 kD, 160 kD, 150 10 kD, 110 kD, 82, kD, and 50 kD.

10

EXAMPLE 3 : Preparation of proteoglycans and acidic glycans from *Mycale lingua*.

15 Extraction of proteoglycan from *Mycale lingua* and isolation of acidic glycans from *Mycale lingua* proteoglycan is performed as described in example 1 for *Microciona prolifera*. The proteoglycan thus obtained has the following characteristics:

20 1) Molecular mass: 12,000 kD ± 20%.
 2) Sedimentation coefficient of S_{20W} 48 ± 20%.
 4) Stability to enzymes: Not digestible with Chondroitinase A, B, C,
Heparinase, Heparitinase, Hyaluronidase and Keratinase.
 5) Gelation: Forms gel in aqueous salt solution containing more than 6mM
CaCl₂ or in deionized water.

25 This proteoglycan consists of approximately 58% protein and 42% carbohydrate by weight. It has an approximate amino acid composition (as measured by HPLC pico-tag) and approximate total sugar composition (as measured by gas chromatography) as shown in Table IV :

Table IV
Amino acid composition and carbohydrate composition

Intact proteoglycan (PG)		
5	amino acid	(mol %)
	Asx	10.8
	Glx	9.6
	Ser	6.3
10	Gly	7.7
	Arg	9.5
	Thr	10.9
	Ala	8.0
	Pro	7.9
15	Tyr	0.5
	Val	9.0
	Met	1.8
	Cys	0.2
	Ile	6.2
20	Leu	6.0
	Phe	5.6
	Total	100.0
	carbohydrate	(mol %)
25	Fuc	29.7
	Xyl	1.0
	GlcUA	11.5
	GalUA	0.8
	Man	11.0
30	Gal	15.3
	Glc	16.7
	GalNAc	6.3
	GlcNAc	7.7
	Total	100.0
35		mol/mol PG
	SO_4^{--}	$\geq 12,000$

Standard deviation is less than 20% of each value. Asx signifies Asn or Asp; Gix signifies Glu or Gln. It is also noted that apparent amounts of Ile and Leu are somewhat variable depending on the preparation. The amount of uronic acid determined colorimetrically is usually 2 times higher than the amount determined by gas chromatography. SO₄²⁻ was determined by HPLC ion chromatography after hydrolysis of PG.

5

EXAMPLE 4 : Preparation of proteoglycans and acidic glycans from *Clionacelata* :

Extraction of two proteoglycans from *Cliona celata* and isolation of acidic glycans from *Cliona celata* proteoglycans is performed as described in example 1 for *Microciona prolifera* with the exception that precipitation with CaCl₂ could be omitted. Two proteoglycan designated CPG1 (more abundant in the first extraction) and CPG2 (more abundant in the second extraction) thus obtained has the following characteristics:

15 1) Molecular mass: CPG1 >20,000 kD ± 20%; CPG2 6,000 kD.
 2) Sedimentation coefficient of CPG1 S_{20W} 125 ± 20%; CPG2 26 S_{20W} ± 20%.
 4) Stability to enzymes: Not digestible with Chondroitinase A, B, C, Heparinase, Heparitinase, Hyaluronidase and Keratinase.
 5) Gelation: Both proteoglycans form viscous gels in aqueous salt solution containing more than 6mM CaCl₂ or in deionized water.

20 CPG1 consists of approximately 26 % protein and 74 % carbohydrate by weight (determined colorimetrically). CPG2 consists of approximately 32 % protein and 68 % carbohydrate by weight. They have an approximate amino acid composition (as measured by HPLC pico-tag) and approximate total sugar composition (as measured by gas chromatography) as shown in Table V :

25

Table V

Amino acid composition and carbohydrate composition

	Intact proteoglycan (CPG1)	(CPG2)
	amino acid (mol %)	(mol %)
	Asx	7.8
	Glx	9.5
5	Ser	11.3
	Gly	10.9
10	Arg	6.0
	Thr	14.1
	Ala	7.7
15	Pro	10.7
	Tyr	0.7
	Val	6.1
	Met	2.4
	Cys	0.2
20	Ile	3.9
	Leu	5.1
	Phe	3.6
	Lys	0.1
	Total	
25	carbohydrate (mol %)	
	Fuc	17.8
	Xyl	2.2
	GlcUA	11.0
	GalUA	1.1
30	Man	5.9
	Gal	12.8
	Glc	18.5
	GalNAc	16.2
	GlcNAc	14.8
35	Total	100.0
	mol/mol PG	mol/mol PG
	$\text{SO}_4^{2-} \geq 20,000$	$\geq 6,000$

Standard deviation is less than 20% of each value. Asx signifies Asn or Asp; Glx signifies Glu or Gln. It is also noted that apparent amounts of Ile and Leu are somewhat variable depending on the preparation. The amount of uronic acid determined colorimetrically is usually 2 times higher than the amount determined by gas chromatography. SO₄²⁻ was determined by HPLC ion chromatography after hydrolysis of PG.

5

EXAMPLE 5 : Preparation of acidic glycans from *Lytechinus pictus* :

Lytechinus pictus sea urchin eggs and/or embryos (from 2 cell stage to pluteus stage) were washed with sterile sea water and pelleted embryos were extracted with water/methanol/chloroform 3/8/4 V/V/V, and the nonlipid fraction was pelleted by centrifugation at 4000 x g for 15 min at +4°C. This extraction is repeated and the pellet is dried under a vacuum. The pellet is wetted in ethanol and resuspended in 0.1 M Tris pH 8, 1mM CaCl₂ and 100-200µg Pronase (Calbiochem) (preincubated for 30 min at 60°C in 0.1M Tris pH 8, 1mM CaCl₂ per 1-2mg dried powder material), and the pellet is digested at 60°C for three days. Two more equivalent portions of preincubated pronase are added at 24 h intervals. DNase I is then added (30µg) and incubation is continued at 37°C in the presence of 10mM MgCl₂. The digested sample is then treated again with pronase and chromatographed through G-25 Sephadex (Pharmacia) column eluted with 10mM pyridine acetate pH 5, void volume fractions are collected and lyophilized, and the glycans thus obtained are dissolved in 50mM NaOH in the presence of 1M NaHBO₄, and incubated at 45°C for 16h (NaOH treatment may also be omitted). The glycans are passed through Dowex AG 50W-X8 column in H⁺ form (Bio-Rad) eluted with water, nonbound glycans are immediately neutralized and electrophoresed on a 5-20% or 10-40% linear polyacrylamide gradient gels (Tris/borate-EDTA), and separated acidic glycans of Mr 200 x 10³ are eluted from gels. (Optionally, the acidic glycans can be separated by gel filtration rather than electrophoresis). The isolated acidic glycan molecules are desalting using P-2 column (Bio-Rad) eluted with 10mM pyridine acetate pH 5, lyophilized and purified by affinity chromatography with the Block 2 monoclonal antibodies of ref Misevic et al mentioned above stored at -20°C.

- 1) Molecular mass: 580 kD ± 20%.
- 2) Sedimentation coefficient 8.5 S_{20w} ± 20%.
- 4) Stability to enzymes: Not digestible with Chondroitinase A, B, C, Heparinase, Heparitinase, Hyaluronidase and Keratinase.
- 35 5) Gelation: self-interaction-oligomerization in aqueous salt solution containing more than 6mM CaCl₂ or in deionized water.

Table VI

		<u>mol carbohydrate</u> <u>mol acidic glycan</u>	(mol %)
5	Fuc	737	25.40
	Xyl	108	3.73
	Gal	39	1.34
	Glc	12	0.41
	Uronic acids	786	27.10
10	GalNAc	506	17.46
	GlcNAc	712	24.56
	Total	2,900	100.00
	mol/mol		
	SO ₄ ²⁻	1.600	

15 Standard deviation is less than 20% of each value. The amount of uronic acid determined colorimetrically is usually 2 times higher than the amount determined by gas chromatography. SO₄²⁻ was determined by HPLC ion chromatography after hydrolysis of PG.

20 EXAMPLE 6 : *Ex vivo stimulation of human NK cells proliferation by Microciona prolifera proteoglycan and by its acidic glycans*

Human peripheral blood mononuclear cell (PBMC) are isolated from 10 ml of blood by centrifugation on Ficoll gradient (Pharmacia). Stimulation of PBMC proliferation with 25 100 µg/ml acidic glycans or proteoglycans is performed in the presence of complete medium (RPMI 1640, 5% human AB serum, 2mM L-Glutamine, 1mM Na pyruvate, non-essential amino acids and 50µg/ml Kanamycin). After 5 days 5U/ml of human recombinant IL-2 is added. One half of medium is changed when it becomes acidic. After 7, 14, 21, 28 and 30 35 days cells were analyzed by FACS using antibodies against following markers: CD3, TCR αβ, TCR γδ, CD4, CD8 - T cells; CD16, CD56 - NK cells; CD20 - B cell; CD14 - monocytes. Results from five different donors after 3 weeks: In the PBMC cultures treated with acidic glycans, NK cells population (CD 16 and CD 56 positive) and (CD3, TCR αβ, TCR γδ, CD4, CD8, CD20 and CD14 negative) increased from 1-5 % to 30-80 % of the total PBMC, whereas untreated controls remained at a level of 1-5 % NK cells. Specific stimulation of NK cells proliferation by glycans was confirmed by ³H thymidine incorporation only in isolated clones of NK cells and not αβT cells isolated from the same 35 PBMC cultures.

EXAMPLE 7 : *Ex vivo* stimulation of human NK cells proliferation by *Mycalia lingua* and *Cliona celata* proteoglycans and by its acidic glycans was similar to *Microciona prolifera* proteoglycan.

EXAMPLE 8 : *Ex vivo* stimulation of human NK cells proliferation by *Lytechinus pictus* acidic glycan with 580 kD was similar to *Microciona prolifera* proteoglycan.

EXAMPLE 9 : Stimulation of human $\gamma\delta$ T cells proliferation (*ex vivo*) by *Microciona prolifera* proteoglycan, *Halichondria panicea* proteoglycan and/or their acidic glycans

10 Same culturing procedure as described in the previous example shows that *Microciona prolifera* acidic glycans stimulate only one subpopulation of $\gamma\delta$ T cells via T cell receptor with an increase from 5% to 20%. *Halichondria panicea* proteoglycan and its acidic glycans stimulate a different population of $\gamma\delta$ T cells from 5% to 70%. These data are confirmed by 3 H thymidine incorporation in isolated clones stimulated by specific acidic glycans.
15

EXAMPLE 10 : Anti-tumorogenic and anti-metastatic activity of proteoglycans from *Microciona prolifera* (*in vivo*)

20 Seven C-57 black mice are injected i.p. with 300 μ g proteoglycan from *Microciona prolifera*/200 μ l 0.2M NaCl, 2mM CaCl₂, 20mM Tris pH 7.4/animal, every day for five days. At day five, animals are injected with 2.5 X 10⁴ B-16 melanoma cells per animal. Animals are immunized for five more days with proteoglycan as described above. The appearance of tumor, tumor growth, survival of animals and appearance of metastasis are observed in immunized animals and compared with control animals injected with buffer. Control animals which have not received proteoglycan all exhibit marked melanoma growth followed by metastasis. Compared to controls, treated animals exhibit a 20% delay in the time of appearance and 50% reduction in growth of syngenic B16 melanomas, a 12% increase in the total time of survival of all immunized mice ($p = 0.0044$), and complete inhibition of metastasis.
25
30

EXAMPLE 11 : Anti-tumorogenic and anti-metastatic activity of proteoglycans and their acidic glycans from *Halichondria panicea* *Mycalia lingua*, *Cliona celata* and *Lytechinus pictus* were similar to *Microciona prolifera* proteoglycan (*in vivo*).

EXAMPLE 12 : Cloning and expression of gene for proteoglycans from *Microciona prolifera*

Proteoglycan (PG) cDNA is isolated from a random-primed cDNA library created using poly(A)⁺RNA from *Microciona prolifera* cells. This cDNA library is screened using the N-terminal amino acid sequence of PG described in example 1 above by colony hybridization techniques, i.e., expressing the library in an expression system, preferably E. coli, lysing the colonies, e.g., on nitrocellulose filters, denaturing their DNA in situ and fixing it on the filter, hybridizing with labeled, preferably radiolabeled, oligonucleotide probes of at least 30 base pairs having cDNA base sequences corresponding to all or a portion of the N-terminal sequence of PG, identifying hybridized colonies, and retrieving the corresponding vectors from the library, using chromosome walking techniques if necessary to isolate and characterize one or more cDNA fragments containing one or more regions coding for glycosylation sites for N-linked glycans. (Note that the cDNA is repetitive, so it is not necessary to clone, isolate and characterize the entire sequence). Once the desired portion of cDNA has been isolated, it is expressed in a suitable expression system, preferably a eukaryotic system, most preferably a sponge. The PG is isolated from the sponge or from the culture medium of the expression system, e.g., using the procedures outlined above.

CLAIMS

1. A fucose-containing proteoglycan or acidic glycan and/or fragment(s) thereof, for use as pharmaceutical.

5

2. A fucose-containing proteoglycan or acidic glycan according to claim 1 capable of being isolated from an organism of all phyla and preferably of the phylum Porifera and/or of the phylum Echinodermata.

10

3. A fucose-containing proteoglycan or acidic glycan according to claim 2 capable of being isolated from a marine sponge of the genus *Microciona* and/or *Halichondria* and/or *Mycale* and/or *Cliona*.

15

4. A fucose-containing proteoglycan or acidic glycan capable of being isolated from a marine sponge of the genus *Halichondria* and/or *Mycale* and/or *Cliona*.

20

5. A fucose-containing acidic glycan capable of being isolated from a sea urchin of the genus *Lytachinus*.

25

6. A fucose-containing acidic glycan according to claim 1,2 or 5, capable of binding to monoclonal antibodies of the type of those named "Block 2" and described in the reference "Misevic, et al., J. Biol. Chem. (1993) 268 : 4922-4929.

30

7. A method of stimulating the proliferation of mammalian NK cells and/or $\gamma\delta T$ cells of larger mammals, e.g., man, comprising contacting said cells with a compound as described in any one of claims 1-6.

35

8. Use of a compound according to any one of claims 1-6 in the manufacture of a medicament for treating cancer or viral or retroviral infections.

30

9. A pharmaceutical composition comprising a compound according to any one of claims 1-6, together with a pharmaceutically acceptable diluent or carrier.

35

10. A kit of parts for *ex vivo* stimulation of proliferation of mammalian NK cells and/or $\gamma\delta T$ cells comprising a compound as described in any one of claims 1-6.

11. A method for screening for or detecting an immunosuppressive compound comprising measuring proliferation of NK cells and/or $\gamma\delta$ T cells in a system containing an NK cell or $\gamma\delta$ T cell stimulatory concentration of a compound as described in any one of claims 1-6 in the presence and absence of a test compound.

5

12. All novel compounds, processes and utilities substantially as described herein.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/IB 95/00208

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/435 C08B37/00 A61K38/17 A61K31/725 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K C08B A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Classification of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF BIOLOGICAL CHEMISTRY, vol.262, no.12, 25 April 1987, BALTIMORE, MD US pages 5870 - 5877 G. MISEVIC ET AL. 'INVOLVEMENT OF CARBOHYDRATES AS MULTIPLE LOW AFFINITY INTERACTION SITES IN THE SELF-ASSOCIATION OF THE AGGREGATION FACTOR FROM THE MARINE SPONGE MICROciona PROLIFERA.' cited in the application see the whole document ----- -/-	4, 12

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered inventive if the document is taken alone or in combination with one or more other such documents, such combination being obvious to a person skilled in the art

"A" document member of the same patent family

Date of the actual completion of the international search 20 June 1995	Date of mailing of the international search report 04.07.95
Name and mailing address of the ISA European Patent Office, P.O. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax (+31-70) 340-3016	Authorized officer Ryckebosch, A

INTERNATIONAL SEARCH REPORT

Intern'l Application No.
PCT/IB 95/00208

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
Category	Citation of document, with indication, where appropriate, of the relevant passages	
X	JOURNAL OF BIOLOGICAL CHEMISTRY, vol.265, no.33, 25 November 1990, BALTIMORE, MD US pages 20577 - 20584 G. MISEVIC ET AL. 'THE SPECIES-SPECIFIC CELL-BINDING SITE OF THE AGGREGATION FACTOR FROM THE SPONGE MICROciona PROLIFERA IS A HIGHLY REPETITIVE NOVEL GLYCAN CONTAINING GLUCURONIC ACID, FUCOSE, AND MANNOSE.' cited in the application see the whole document ---	4,12
X	JOURNAL OF BIOLOGICAL CHEMISTRY, vol.268, no.7, 5 March 1993, BALTIMORE, MD US pages 4922 - 4929 G. MISEVIC ET AL. 'CARBOHYDRATE-CARBOHYDRATE INTERACTIONS OF A NOVEL ACIDIC GLYCAN CAN MEDIATE SPONGE CELL ADHESION.' cited in the application see the whole document	4,6,12
X	JOURNAL OF CELLULAR BIOCHEMISTRY, vol.53, no.2, October 1993, NEW YORK, N.Y., US pages 98 - 113 E. PAPAKONSTANTINOU ET AL. 'ISOLATION AND CHARACTERIZATION OF A NEW CLASS OF ACIDIC GLYCANS IMPLICATED IN SEA URCHIN EMBRYONAL CELL ADHESION.' see the whole document -----	5,6,12
1		

INTERNATIONAL SEARCH REPORT

Int'l. animal application No.
PCT/IB 95/00208

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 7(as far as relating to an in vivo method) is directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims it is covered by claims Nos.:

Itemmark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.